Compare iShares International Treasury Bond ETF (IGOV) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Mesoblast Limited — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B), while Mesoblast Limited trades at $14.18 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and iShares International Treasury Bond ETF is more actively traded (693,740 versus 239,027). Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Mesoblast Limited for 14 Days on average.
| IGOV | MESO | |
|---|---|---|
Market Cap | $1.30B | $1.75B |
Volume | 693,740 | 239,027 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $20.96 |
52-Week Low | $39.65 | $13.19 |
Typical Hold Time | 92 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.75 with minimal daily movement (+0.13%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces significant resistance at $40 across multiple levels. Financial ratios are unavailable in current data, limiting fundamental assessment.
The stock's outlook remains cautious due to technical weakness and limited fundamental visibility. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETFs may benefit. Investors require updated financial disclosures to properly evaluate valuation and growth prospects amid current market volatility.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
